Abstract
Background and Aims : PCSK9 is a key regulator of cholesterol levels by its action on LDL receptors and would promotes inflammation and atherogenesis. PCSK9 represents a novel pharmacological target for hypercholesterolemia Frequently prescribed lipid-lowering therapy (LLT), particularly statins, has been reported to increase circulating PCSK9, decreasing the effect of statins on lowering LDL-C. Little is known -and with contradictory results- about the effect of statin+ezetimibe (S+E) combination on PCSK9 levels.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
